As expected, AGN.c's DMT for stroke phase 1 trial went well and was found safe to proceed to phase 2 trials. AGN’s safety review committee has also approved moving the study forward with the next cohort at an escalated dose after observing no safety or tolerability issues.
- Phase 1’s purpose is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by a 6 hour infusion.
- Once the correct dose amount has been established in the first part of the study, the second part of the study will include dosing subjects for 6 hours, with repeated dosing over a two-week period.
- Additionally, they’re already designing phase 2 which is expected to dose patients immediately following an ischemic stroke diagnosis and will test the effects of DMT versus placebo on patient recovery to see DMT’s neuroplasticity effects.
https://ca.finance.yahoo.com/news/algernon-neuroscience-provides-phase-1-120000274.html
Great to see the continued developments here especially considering the past studies/evidence that are pointing toward DMT being a potentially revolutionary drug in the stroke recovery space. Additionally, it could further legitimize psychedelics as an effective drug for health and wellness. Once phase 2 commences there’s going to be a lot to look out for considering the current valuation of just $4.8M.